Compare Stocks

Enter up to five stock symbols separated by a comma or space (ex. BAC,WFC,JPM,LON:BARC).
Date Range: 

 Elekta AB (publ)Burning Rock BiotechCareDxVeracyteInvitae
SymbolOTCMKTS:EKTAYNASDAQ:BNRNASDAQ:CDNANASDAQ:VCYTNYSE:NVTA
Price Information
Current Price$13.81$29.56$74.27$48.17$37.64
52 Week RangeHoldBuyBuyBuyBuy
MarketRank™
Overall Score1.00.91.01.41.6
Analysis Score0.01.51.53.33.3
Community Score2.12.52.73.02.5
Dividend Score0.80.00.00.00.0
Ownership Score0.00.00.00.01.7
Earnings & Valuation Score1.90.60.60.60.6
Analyst Ratings
Consensus RecommendationHoldBuyBuyBuyBuy
Consensus Price TargetN/A$32.30$75.83$66.14$49.33
% Upside from Price TargetN/A9.27% upside2.10% upside37.31% upside31.07% upside
Trade Information
Market Cap$5.28 billion$3.09 billion$3.85 billion$3.23 billion$7.40 billion
Beta0.85N/A0.840.772.11
Average Volume3,030381,110780,442995,6184,592,313
Sales & Book Value
Annual Revenue$1.44 billionN/A$127.07 million$120.37 million$216.82 million
Price / Sales3.68N/A30.2926.8134.14
Cashflow$0.62 per shareN/AN/AN/AN/A
Price / Cash22.10N/AN/AN/AN/A
Book Value$2.26 per shareN/A$2.33 per share$4.90 per share$3.93 per share
Price / Book6.11N/A31.889.839.58
Profitability
Net Income$132.74 millionN/A$-21,970,000.00$-12,600,000.00$-241,960,000.00
EPSN/AN/A($0.52)($0.27)($2.28)
Trailing P/E Ratio39.370.00N/AN/AN/A
Forward P/E Ratio29.38N/AN/AN/AN/A
P/E GrowthN/AN/AN/AN/AN/A
Net MarginsN/AN/A-11.79%-30.46%-183.50%
Return on Equity (ROE)N/AN/A-10.95%-12.27%-81.19%
Return on Assets (ROA)N/AN/A-7.94%-10.95%-37.28%
Dividend
Annual Payout$0.14N/AN/AN/AN/A
Dividend Yield1.01%N/AN/AN/AN/A
Three-Year Dividend GrowthN/AN/AN/AN/AN/A
Payout RatioN/AN/AN/AN/AN/A
Years of Consecutive Dividend GrowthN/AN/AN/AN/AN/A
Debt
Debt-to-Equity RatioN/AN/AN/AN/A0.68%
Current RatioN/A9.84%4.14%26.60%4.09%
Quick RatioN/A9.59%3.98%26.28%4.09%
Ownership Information
Institutional Ownership Percentage0.02%15.79%N/AN/A78.60%
Insider Ownership PercentageN/AN/A3.10%8.30%2.90%
Miscellaneous
Employees4,0009384563202,100
Shares Outstanding382.03 million104.55 million51.82 million67.00 million196.66 million
Next Earnings DateN/A6/9/2021 (Estimated)4/29/2021 (Estimated)5/5/2021 (Estimated)5/4/2021 (Estimated)
OptionableNot OptionableNot OptionableOptionableOptionableOptionable
SourceHeadline
Is Invitae a Buy? - Motley FoolIs Invitae a Buy? - Motley Fool
fool.com - April 17 at 8:11 AM
1 Number That Should Shock Fulgent Genetics Investors1 Number That Should Shock Fulgent Genetics Investors
finance.yahoo.com - April 17 at 8:11 AM
Is Invitae a Buy?Is Invitae a Buy?
finance.yahoo.com - April 17 at 8:11 AM
Invitae Co. (NYSE:NVTA) Insider Katherine Stueland Sells 19,893 SharesInvitae Co. (NYSE:NVTA) Insider Katherine Stueland Sells 19,893 Shares
americanbankingnews.com - April 15 at 10:32 PM
Invitaes share price wobbles despite genomics tie-up - CMC MarketsInvitae's share price wobbles despite genomics tie-up - CMC Markets
cmcmarkets.com - April 15 at 2:53 PM
Study finds risk-causing genetic changes in nearly 1 in 6 patients with colorectal cancer - PRNewswireStudy finds risk-causing genetic changes in nearly 1 in 6 patients with colorectal cancer - PRNewswire
prnewswire.com - April 15 at 9:53 AM
Invitaes (NVTA) mission is to bring comprehensive genetic information into mainstream medical practice to improve the quality of healthcare for billions of people. www.invitae.com (PRNewsFoto/Invitae Corporation) - WFMZ AllentownInvitae's (NVTA) mission is to bring comprehensive genetic information into mainstream medical practice to improve the quality of healthcare for billions of people. www.invitae.com (PRNewsFoto/Invitae Corporation) - WFMZ Allentown
wfmz.com - April 15 at 9:53 AM
Study finds risk-causing genetic changes in nearly 1 in 6 patients with colorectal cancerStudy finds risk-causing genetic changes in nearly 1 in 6 patients with colorectal cancer
finance.yahoo.com - April 15 at 9:53 AM
Invitae, PCT Therapeutics, Genome Medical Partner to Offer Genetic Testing for Cerebral Palsy - GenomeWebInvitae, PCT Therapeutics, Genome Medical Partner to Offer Genetic Testing for Cerebral Palsy - GenomeWeb
genomeweb.com - April 14 at 11:27 PM
Invitae Corporations $1.15 Billion Notes Private Placement – Global Legal Chronicle - Global Legal ChronicleInvitae Corporation's $1.15 Billion Notes Private Placement – Global Legal Chronicle - Global Legal Chronicle
globallegalchronicle.com - April 14 at 3:24 AM
Invitae Corporation (NYSE:NVTA) surprises Wall Street with -1.03% stock price lossInvitae Corporation (NYSE:NVTA) surprises Wall Street with -1.03% stock price loss
marketingsentinel.com - April 13 at 10:24 PM
Is Invitae Corp (NVTA) Stock About to Get Hot Tuesday? - InvestorsObserverIs Invitae Corp (NVTA) Stock About to Get Hot Tuesday? - InvestorsObserver
investorsobserver.com - April 13 at 5:24 PM
Do Institutions Own Invitae Corporation (NYSE:NVTA) Shares? - Yahoo FinanceDo Institutions Own Invitae Corporation (NYSE:NVTA) Shares? - Yahoo Finance
finance.yahoo.com - April 13 at 12:24 PM
Do Institutions Own Invitae Corporation (NYSE:NVTA) Shares?Do Institutions Own Invitae Corporation (NYSE:NVTA) Shares?
finance.yahoo.com - April 13 at 12:24 PM
Top Five Articles on GenomeWeb Last Week: Invitae, Cancer, Illumina, and More - GenomeWebTop Five Articles on GenomeWeb Last Week: Invitae, Cancer, Illumina, and More - GenomeWeb
genomeweb.com - April 12 at 8:08 PM
Ark Invest analyst breaks down Adaptive Biotechnologies and Invitae - CNBCArk Invest analyst breaks down Adaptive Biotechnologies and Invitae - CNBC
cnbc.com - April 12 at 8:08 PM
Invitae Corporation (NYSE:NVTA) -0.71% Decline Turns Away Investor Interest In Company’s StockInvitae Corporation (NYSE:NVTA) -0.71% Decline Turns Away Investor Interest In Company’s Stock
stocksregister.com - April 12 at 3:04 PM
Invitae (NYSE:NVTA) Receives "Buy" Rating from SVB LeerinkInvitae (NYSE:NVTA) Receives "Buy" Rating from SVB Leerink
americanbankingnews.com - April 11 at 6:22 AM
Invitae Stock Price: $48 Target By Oppenheimer - Pulse 2.0Invitae Stock Price: $48 Target By Oppenheimer - Pulse 2.0
pulse2.com - April 10 at 6:39 AM
Invitae Opens Genetic Testing to Adults With ALS Symptoms or... - ALS News TodayInvitae Opens Genetic Testing to Adults With ALS Symptoms or... - ALS News Today
alsnewstoday.com - April 9 at 12:42 PM
Invitae to Provide Genetic Testing Within eMERGE Population Screening Study - GenomeWebInvitae to Provide Genetic Testing Within eMERGE Population Screening Study - GenomeWeb
genomeweb.com - April 9 at 1:00 AM
Is NVTA Stock A Buy or Sell? - Yahoo FinanceIs NVTA Stock A Buy or Sell? - Yahoo Finance
finance.yahoo.com - April 8 at 8:00 PM
Invitae joins NHGRI funded eMERGE Network - Seeking AlphaInvitae joins NHGRI funded eMERGE Network - Seeking Alpha
seekingalpha.com - April 8 at 2:59 PM
Invitae (NYSE:NVTA) Shares Up 4.5%Invitae (NYSE:NVTA) Shares Up 4.5%
americanbankingnews.com - April 8 at 11:50 AM
Global Precision Psychiatry Market (2021 to 2026) - Featuring ARUP Laboratories, Invitae & OPKO Health Among Others - ResearchAndMarkets.com - Business WireGlobal Precision Psychiatry Market (2021 to 2026) - Featuring ARUP Laboratories, Invitae & OPKO Health Among Others - ResearchAndMarkets.com - Business Wire
businesswire.com - April 8 at 9:59 AM
Invitae (NYSE:NVTA) Upgraded to Outperform by OppenheimerInvitae (NYSE:NVTA) Upgraded to Outperform by Oppenheimer
marketbeat.com - April 5 at 7:40 AM
3 Groundbreaking Genomics Stocks to Buy Now (NVTA)3 Groundbreaking Genomics Stocks to Buy Now (NVTA)
marketbeat.com - January 8 at 6:58 PM
DateCompanyBrokerageAction
3/18/2021Elekta AB (publ)JPMorgan Chase & Co.Downgrade
1/20/2021Elekta AB (publ)Berenberg BankReiterated Rating
1/7/2021Elekta AB (publ)Northland SecuritiesInitiated Coverage
12/9/2020Elekta AB (publ)Morgan StanleyDowngrade
5/7/2020Elekta AB (publ)UBS GroupDowngrade
2/21/2020Elekta AB (publ)Pareto SecuritiesDowngrade
7/16/2019Elekta AB (publ)Jefferies Financial GroupUpgrade
7/13/2020Burning Rock BiotechBank of AmericaInitiated Coverage
7/7/2020Burning Rock BiotechCowenInitiated Coverage
3/3/2021CareDxRaymond JamesLower Price Target
2/26/2021CareDxHC WainwrightDowngrade
1/12/2021CareDxPiper SandlerBoost Price Target
1/4/2021CareDxCraig HallumBoost Price Target
12/17/2020CareDxBTIG ResearchBoost Price Target
4/14/2021VeracyteNeedham & Company LLCReiterated Rating
2/25/2021VeracyteSVB LeerinkBoost Price Target
1/27/2021VeracyteTruistInitiated Coverage
12/17/2020VeracyteLake Street CapitalBoost Price Target
11/9/2020VeracyteKeyCorpInitiated Coverage
11/2/2020VeracyteWilliam BlairReiterated Rating
4/5/2021InvitaeOppenheimerUpgrade
2/25/2021InvitaeLADENBURG THALM/SH SHUpgrade
7/1/2020InvitaeBenchmarkDowngrade
(Data available from 4/18/2018 forward. View 10+ years of historical ratings with our analyst ratings screener.)
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security. Learn more.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.